Prophylactic vaccine and adjuvant

TapImmune’s revolutionary vaccine and adjuvant utilizes components of the major histocompatibility (MHC) class I antigen processing pathway in order to increase the immune priming and protection against foreign pathogens.  This in turn makes the production and utilization of vaccines much more responsive in times of acute need. A variety of adjuvants have been developed that either suffer from substantial toxicity or cannot be implemented because their mode of action is obscure.  TapImmune’s prophylactic vaccine & adjuvant appears to overcome these challenges.

Although protective vaccines against various infectious diseases, such as AIDS and smallpox, are a societal priority, they remain a scientific challenge to develop and optimize. The threat of bioterrorism has increased the need and urgency for new and effective vaccines. Unfortunately the penalty of implementing new vaccines includes the toxic side effects to which the vaccine candidate is exposed.  A significant number of individuals inoculated with a new vaccine against smallpox, for example, may suffer toxicity due to vaccination.   Another challenge to overcome in the production of vaccines is the creation of sufficient doses to vaccinate a large population.

TapImmune’s vaccine platform demonstrates that even low, suboptimal doses of vaccines, confers protective immunity against lethal viral loads during viral challenges. This is a new paradigm in the treatment of infectious disease and could significantly advance the development of new vaccines as well as improve those that already exist.